Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.08. | Filament Health Corp. reports Q2 results | 2 | Seeking Alpha | ||
11.08. | Filament Health Announces Second Quarter 2025 Financial Results And Operational Highlights | 1 | CNW | ||
31.07. | Filament Health Announces First-ever Compassionate Use Approval For Psilocybin In The European Union | 1 | CNW | ||
24.07. | Filament Health Announces Two Phase 2 Research Trials In Partnership With University College London | 1 | CNW | ||
08.07. | Jaguar Health, Inc.: Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health | 505 | ACCESS Newswire | Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 /
Jaguar Health, Inc.
(NASDAQ:JAGX)
... ► Artikel lesen | |
07.07. | Filament Health Announces Fda Authorization Of Phase 2 Clinical Trial Studying Psilocybin For Alcohol Use Disorder And Post-traumatic Stress Disorder In Veterans And First Responders | 1 | CNW | ||
17.06. | Filament Health Enters Into Exclusive License Agreement With University Of Alabama At Birmingham For Data From A Clinical Trial Of Psilocybin For The Treatment Of Cocaine Use Disorder | 2 | CNW | ||
FILAMENT HEALTH Aktie jetzt für 0€ handeln | |||||
11.06. | Filament Health Announces Authorization Of Phase 2 Clinical Trial Studying Botanical Psilocybin For Prolonged Grief Disorder | 1 | CNW | ||
28.05. | Filament Health Announces Transition From Otcqb To Otc Pink Limited | 3 | CNW | ||
22.05. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.05.2025 | 767 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 22.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.05.2025.ISIN NameCA31685W1068 FILAMENT... ► Artikel lesen | |
22.05. | XFRA 7QS: AUSSETZUNG/SUSPENSION | 242 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFILAMENT HEALTH... ► Artikel lesen | |
20.05. | Filament Health Corp: Filament shares to delist from Cboe Canada May 21 | 1 | Stockwatch | ||
19.05. | Filament Health Corp.: Filament Health Announces Voluntary Delisting From Cboe Canada | 186 | PR Newswire | VANCOUVER, BC, May 19, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
09.05. | Filament Health reports Q1 results | 1 | Seeking Alpha | ||
09.05. | Filament Health Corp.: Filament Health Announces First Quarter 2025 Financial Results And Operational Highlights | 91 | PR Newswire | VANCOUVER, BC, May 8, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (CBOE: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
04.04. | Filament Health Corp.: Filament Health Announces Private Placement And Intention To Voluntarily Delist From Cboe Canada | 170 | PR Newswire | Financing driven by existing investor Negev and Filament's Board of Directors
Company also announces intention to voluntarily delist from Cboe Canada
VANCOUVER... ► Artikel lesen | |
01.04. | Filament Health Corp.: Filament Health Reports Q4 And Year End 2024 Financial Results And Operational Highlights | 131 | PR Newswire | VANCOUVER, BC, April 1, 2025 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic... ► Artikel lesen | |
17.03. | Filament Health Corp.: Filament Health Announces Positive Data From Phase 2 Study Of Pex010 In Patients With Alcohol Use Disorder | 109 | PR Newswire | Open-label study at Psychiatric Centre Copenhagen found that alcohol consumption significantly decreased amongst participants dosed with Filament's botanical psilocybin... ► Artikel lesen | |
06.02. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference | 487 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as... ► Artikel lesen | |
07.01. | Jaguar Health, Inc.: Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum | 489 | ACCESS Newswire | Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 27,520 | +0,60 % | Fast 150 % Kurschance! Plug Power, Bayer, Planethic Group Aktie | Bietet sich bei der Planethic Group (vormals Veganz Group) die Kaufchance des Herbstes? Analysten sehen jedenfalls über 100 % Kurspotenzial. Die jüngste Korrektur scheint übertrieben und lockt zum Einstieg.... ► Artikel lesen | |
AURORA CANNABIS | 4,375 | -1,35 % | How to Play Aurora Cannabis Stock Amid Renewed Legalization Hopes? | ||
CANOPY GROWTH | 1,150 | -2,71 % | Cannabis-Aktien mit Trump-Schub: Bioxyne, Aurora und Canopy Growth im Fokus | ||
TILRAY BRANDS | 1,247 | -2,62 % | Tilray Brands-Aktie sorgt für Aufsehen - was jetzt passiert, überrascht selbst erfahrene Anleger! | ||
INNOCAN PHARMA | 9,800 | -2,00 % | Breaking News: InnoCan Pharma spielt den nächsten Patent-Trumpf aus! | ||
CRONOS GROUP | 2,146 | -0,65 % | Cronos Group Inc.: Cronos Group Reports 2025 Second Quarter Results | Net revenue in Q2 2025 increased by 21% year-over-year PEACE NATURALS® retained its position as the number one cannabis brand in Israel1 Highest-ever international and Israel revenue, fueled by strong... ► Artikel lesen | |
SYNBIOTIC | 2,585 | -2,08 % | EQS-News: SYNBIOTIC SE: SYNBIOTIC begrüßt Antrag der Grünen zum Nutzhanfliberalisierungsgesetz und fordert Sachlichkeit in der Medizinalcannabis-Debatte | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Stellungnahme
SYNBIOTIC begrüßt Antrag der Grünen zum Nutzhanfliberalisierungsgesetz und fordert Sachlichkeit in der Medizinalcannabis-Debatte... ► Artikel lesen | |
GREEN THUMB INDUSTRIES | 6,250 | -5,09 % | Top U.S. Marijuana Stocks to Watch in October 2025: Trulieve, Curaleaf, and Green Thumb Dominate the Industry | ||
CHRISTINA LAKE CANNABIS | 0,020 | 0,00 % | Christina Lake Cannabis Corp: Christina Lake arranges $1.5M revolving credit line | ||
AXSOME THERAPEUTICS | 112,50 | -0,66 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® 2Q 2025 net product sales of $119.6 million, representing growth of... ► Artikel lesen | |
JAZZ PHARMACEUTICALS | 118,85 | +0,25 % | Avadel Reaches Global Settlement With Jazz Pharmaceuticals | WASHINGTON (dpa-AFX) - Avadel Pharmaceuticals plc (AVDL) on Wednesday announced a global settlement resolving all litigation with Jazz Pharmaceuticals Inc. (JAZZ).Under the terms of the settlement... ► Artikel lesen | |
JAGUAR HEALTH | 1,890 | -4,06 % | Jaguar Health, Inc.: Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease | Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral... ► Artikel lesen | |
TRULIEVE CANNABIS | 6,305 | -5,12 % | Trulieve Cannabis Corp: Trulieve to hold Q3 results call Nov. 5 | ||
CORBUS PHARMACEUTICALS | 15,900 | -4,79 % | Piper Sandler raises Corbus Pharmaceuticals stock price target on promising cancer drug data | ||
AVALO THERAPEUTICS | 14,260 | -4,93 % | Avalo Therapeutics: Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates | Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately... ► Artikel lesen |